title: Bioactive porous beads as an injectable urethral bulking agent: in vivo animal study for the treatment of urinary incontinence.
abstract: In our previous study, growth factor (basic fibroblast growth factor [bFGF] or vascular endothelial growth factor)-immobilized polycaprolactone (PCL)/Pluronic F127 porous beads were fabricated by an isolated particle-melting/melt-molding particulate-leaching method. The growth factors were easily immobilized onto the pore surfaces of the PCL/F127 beads via heparin binding, and were continuously released for up to 28 days. In this study, the growth factor-immobilized porous beads were investigated for their potential use as an injectable urethral bulking agent for the treatment of stress urinary incontinence (SUI). From the in vivo study using Sprague-Dawley rats as an urinary incontinent animal model, it was observed that the growth factor (bFGF or vascular endothelial growth factor)-immobilized porous beads had effective cure behaviors for SUI as follows: the narrowed urethral lumen and the regeneration of smooth muscle around the urethra. In particular, the bFGF-immobilized PCL/F127 porous beads showed desirable smooth muscle regeneration and electrical contractility, which indicates it can be a good candidate as an injectable bioactive bulking agent for the treatment of SUI.
authors.affiliation: Department of Advanced Materials, Hannam University, Daejeon, South Korea.
authors.forename: In Gul
authors.initials: IG
authors.lastname: Kim
authors.forename: Se Heang
authors.initials: SH
authors.lastname: Oh
authors.forename: Ji Young
authors.initials: JY
authors.lastname: Lee
authors.forename: Ji Youl
authors.initials: JY
authors.lastname: Lee
authors.forename: Jin Ho
authors.initials: JH
authors.lastname: Lee
mesh_terms: D000818:Animals; D001672:Biocompatible Materials / Q000494:pharmacology*; D055724:Electrophysiological Phenomena / Q000187:drug effects; D055767:Immobilized Proteins / Q000494:pharmacology; D007150:Immunohistochemistry; D066298:In Vitro Techniques; D007267:Injections; D036341:Intercellular Signaling Peptides and Proteins / Q000494:pharmacology*; D008855:Microscopy, Electron, Scanning; D008863:Microspheres; D009119:Muscle Contraction / Q000187:drug effects; D020442:Poloxamer / Q000494:pharmacology*; D011091:Polyesters / Q000494:pharmacology*; D016062:Porosity / Q000187:drug effects; D011312:Pressure; D051381:Rats; D017207:Rats, Sprague-Dawley; D014521:Urethra / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D014549:Urinary Incontinence / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*
chemical_list: D001672:Biocompatible Materials; D055767:Immobilized Proteins; D036341:Intercellular Signaling Peptides and Proteins; D011091:Polyesters; D020442:Poloxamer; C016240:polycaprolactone